These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24453716)

  • 1. A comprehensive cost-effectiveness analysis of treatments for multiple sclerosis.
    Newton AN; Stica CM
    Int J MS Care; 2011; 13(3):128-35. PubMed ID: 24453716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years.
    Oleen-Burkey M; Cyhaniuk A; Swallow E
    J Med Econ; 2013; 16(3):397-406. PubMed ID: 23301877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.
    Sánchez-de la Rosa R; Sabater E; Casado MA; Arroyo R
    J Med Econ; 2012; 15(3):424-33. PubMed ID: 22217249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E; Meyer K
    Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.
    Dembek C; White LA; Quach J; Szkurhan A; Rashid N; Blasco MR
    Eur J Health Econ; 2014 May; 15(4):353-62. PubMed ID: 23615954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.
    Wong J; Gomes T; Mamdani M; Manno M; O'Connor PW
    Can J Neurol Sci; 2011 May; 38(3):429-33. PubMed ID: 21515501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
    Sanford M; Lyseng-Williamson KA
    Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis.
    Becker RV; Dembek C
    J Manag Care Pharm; 2011 Jun; 17(5):377-81. PubMed ID: 21657808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study.
    Beer K; Müller M; Hew-Winzeler AM; Bont A; Maire P; You X; Foulds P; Mårlind J; Curtius D
    BMC Neurol; 2011 Nov; 11():144. PubMed ID: 22074056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
    Nuijten M; Mittendorf T
    Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
    Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
    Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
    Minagara A; Murray TJ;
    Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis.
    Moses H; Brandes DW
    Curr Med Res Opin; 2008 Sep; 24(9):2679-90. PubMed ID: 18694542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.